Uribegro 25 – Mirabegron 25mg Extended Release Tablet Uribegro 50 – Mirabegron 50mg Extended Release Tablet Uribegro S 25 – Mirabegron 25 mg Extended Release + Solifenacin 5mg Tablet Uribegro S 50 – Mirabegron 50 mg Extended Release + Solifenacin 5mg Tablet
Uribegro 25 – Mirabegron 25mg Extended Release Tablet Uribegro 50 – Mirabegron 50mg Extended Release Tablet Uribegro S 25 – Mirabegron 25 mg Extended Release + Solifenacin 5mg Tablet Uribegro S 50 – Mirabegron 50 mg Extended Release + Solifenacin 5mg Tablet
URIBEGRO is a beta-3 adrenergic agonist indicated for the treatment of:
How it works
URIBEGRO is a beta-3 adrenergic agonist
Indications
URIBEGRO is a beta-3 adrenergic agonist indicated for the treatment of:
Dosage
The recommended starting dose of URIBEGRO is 25 mg orally once daily, either alone or in combination with solifenacin succinate 5 mg orally once daily.After 4 to 8 weeks, the URIBEGRO dose may be increased to 50 mg orally once daily
Side Effects
Most commonly reported adverse reactions with URIBEGRO monotherapy in adult patients with OAB (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection, and headache
Contraindication
Hypersensitivity to mirabegron or any inactive ingredients
Copyright © 2020 tasmed
.png)
